Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29600284
Publication Date : //

Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Artificial Invaplex.


The native Invaplex (Invaplex) vaccine and adjuvant is an ion exchange-purified product derived from the water extract of virulent species. The key component of Invaplex is a high-molecular-mass complex (HMMC) consisting of the lipopolysaccharide (LPS) and the invasin proteins IpaB and IpaC. To improve product purity and immunogenicity, artificial Invaplex (Invaplex) was developed using recombinant IpaB and IpaC proteins and purified LPS to assemble an HMMC consisting of all three components. Characterization of Invaplex by various methods demonstrated similar characteristics as the previously reported HMMC in Invaplex. The well-defined Invaplex vaccine consistently contained greater quantities of IpaB, IpaC, and LPS than Invaplex. Invaplex and Invaplex immunogenicities were compared in mouse and guinea pig dose escalation studies. In both models, immunization induced antibody responses specific for Invaplex and LPS while Invaplex induced markedly higher anti-IpaB and -IpaC serum IgG and IgA endpoint titers. In the murine model, homologous protection was achieved with 10-fold less Invaplex than Invaplex and mice receiving Invaplex lost significantly less weight than mice receiving the same amount of Invaplex. Moreover, mice immunized with Invaplex were protected from challenge with both homologous and heterologous serotypes. Guinea pigs receiving approximately 5-fold less Invaplex compared to cohorts immunized with Invaplex were protected from ocular challenge. Furthermore, adjuvanticity previously attributed to Invaplex was retained with Invaplex. The second-generation Invaplex vaccine, Invaplex, offers significant advantages over Invaplex in reproducibility, flexible yet defined composition, immunogenicity, and protective efficacy. species are bacteria that cause severe diarrheal disease worldwide, primarily in young children. Treatment of shigellosis includes oral fluids and antibiotics, but the high burden of disease, increasing prevalence of antibiotic resistance, and long-term health consequences clearly warrant the development of an effective vaccine. One vaccine under development is termed the invasin complex or Invaplex and is designed to drive an immune response to specific antigens of the bacteria in an effort to protect an individual from infection. The work presented here describes the production and evaluation of a new generation of Invaplex. The improved vaccine stimulates the production of antibodies in immunized mice and guinea pigs and protects these animals from infection. The next step in the product's development will be to test the safety and immune response induced in humans immunized with Invaplex.

Authors : Turbyfill K Ross , Clarkson Kristen A , Vortherms Anthony R , Oaks Edwin V , Kaminski Robert W ,

Related products :

Catalog number Product name Quantity
IM20 Biotinylated Antigen Coated Immunogenicity Kit ;Kit for immunogenicity testing
IM10 Passive Coated Immunogenicity Kit ;Kit for immunogenicity testing
B445 CAL Broth (Cellobiose Arginine Lysine Broth) USE : For isolation and biochemical characterization of Yersinia enterocolitica. 5x500gm
B444 CAL Agar (Cellobiose Arginine Lysine Agar) USE For isolation and biochemical characterization of Yersinia enterocolitica. Qty per Litre of Medium: 46
B444 CAL Agar (Cellobiose Arginine Lysine Agar) USE : For isolation and biochemical characterization of Yersinia enterocolitica. 5x500gm
B445 CAL Broth (Cellobiose Arginine Lysine Broth) USE For isolation and biochemical characterization of Yersinia enterocolitica. Qty per Litre of Medium: 26
RG-1001 CyAL-5 cRGD, fluorescence imaging agent for target of avЯ3 expression in the neovasculature, tumor cells, angiogenesis growth and treatment efficacy
IM107 FG Blocker, 1L ;For immunogenicity testing
IM115 CHO HCP Antigen, 1mg_mL ;For immunogenicity testing
IM103 Conjugate Diluent, 1L ;For immunogenicity testing
IM101 Coating Buffer, 1L ;For immunogenicity testing
IM118 HSA Antigen, 1mg_mL ;For immunogenicity testing
IM112 BSA Antigen, 1mg_mL ;For immunogenicity testing
IM50 Human IgG Subclass Kit ;Kit for immunogenicity testing
IM117 Goat IgG Antigen, 1mg_mL ;For immunogenicity testing
IM123 NS_0 HCP Antigen, 1mg_mL ;For immunogenicity testing
IM125 SP2_0 HCP Antigen, 1mg_mL ;For immunogenicity testing
IM116 E. coli HCP Antigen, 1mg_mL ;For immunogenicity testing
IM113 Bovine IgG Antigen, 1mg_mL ;For immunogenicity testing
IM141 Human IgD Antigen, 1mg_mL ;For immunogenicity testing
IM104 Sample Diluent, 500mL ;For immunogenicity testing
IM103-500 Conjugate Diluent, 500mL ;For immunogenicity testing
IM40 Human Immunoglobulin Screening Kit ;Kit for immunogenicity testing
IM122 Mouse IgG Antigen, 1mg_mL ;For immunogenicity testing
IM121 Insulin Antigen, 1mg_mL ;For immunogenicity testing


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur